Log in

NASDAQ:CORI - Corium International Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume577,723 shs
Market Capitalization$459.65 million
P/E RatioN/A
Dividend YieldN/A
Beta0.87
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CORI
CUSIPN/A
Phone650-298-8255

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.86 million
Book Value$0.45 per share

Profitability

Net Income$-47,790,000.00
Net Margins-155.21%

Miscellaneous

EmployeesN/A
Market Cap$459.65 million
Next Earnings DateN/A
OptionableOptionable

Receive CORI News and Ratings via Email

Sign-up to receive the latest news and ratings for CORI and its competitors with MarketBeat's FREE daily newsletter.


Corium International (NASDAQ:CORI) Frequently Asked Questions

What is Corium International's stock symbol?

Corium International trades on the NASDAQ under the ticker symbol "CORI."

How were Corium International's earnings last quarter?

Corium International Inc (NASDAQ:CORI) posted its earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks' consensus estimate of ($0.38) by $0.04. The biopharmaceutical company had revenue of $7.67 million for the quarter, compared to analysts' expectations of $6.72 million. Corium International had a negative return on equity of 276.89% and a negative net margin of 155.21%. View Corium International's Earnings History.

Has Corium International been receiving favorable news coverage?

News articles about CORI stock have been trending very negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Corium International earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for Corium International.

Who are some of Corium International's key competitors?

What other stocks do shareholders of Corium International own?

Who are Corium International's key executives?

Corium International's management team includes the folowing people:
  • Mr. Peter D. Staple, Pres, CEO & Director (Age 66)
  • Mr. Robert S. Breuil, Chief Financial Officer (Age 56)
  • Dr. Parminder Singh, CTO & VP of R&D (Age 54)
  • Mr. Timothy D. Sweemer CPA, Chief Accounting Officer, VP of Admin. & Sec.
  • Ms. Christina Dickerson, VP of Corp. Devel.

How big of a company is Corium International?

Corium International has a market capitalization of $0.00 and generates $31.86 million in revenue each year. The biopharmaceutical company earns $-47,790,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. View Additional Information About Corium International.

What is Corium International's official website?

The official website for Corium International is http://www.coriumgroup.com/.

How can I contact Corium International?

Corium International's mailing address is 235 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-298-8255 or via email at [email protected]


MarketBeat Community Rating for Corium International (NASDAQ CORI)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  320 (Vote Outperform)
Underperform Votes:  262 (Vote Underperform)
Total Votes:  582
MarketBeat's community ratings are surveys of what our community members think about Corium International and other stocks. Vote "Outperform" if you believe CORI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel